Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis

@article{Cipriani2016ComparativeEA,
  title={Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis},
  author={Andrea Cipriani and Xinyu Zhou and Cinzia del Giovane and Sarah Elisabeth Hetrick and B. Qin and Craig Whittington and David Coghill and Yuqing Zhang and Philip L Hazell and Stefan Leucht and Pim Cuijpers and Juncai Pu and David Cohen and Arun V Ravindran and Yiyun Liu and Kurt Michael and Lining Yang and Lanxiang Liu and Peng Xie},
  journal={The Lancet},
  year={2016},
  volume={388},
  pages={881-890}
}

Figures and Tables from this paper

Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis
TLDR
This NMA will provide the most up to date and clinically useful information about the comparative efficacy and acceptability of antidepressants, psychological intervention and their combination in the acute treatment of children and adolescents with depressive disorder.
Comparative efficacy and acceptability of antidepressants , psychological interventions , and their combination for depressive disorder in children and adolescents
TLDR
This work aims to compare and rank in a network meta-analysis the commonly used psychological, pharmacological and combined interventions for depressive disorder in children and adolescents.
Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysis
TLDR
This project systematically searches for all double-blind randomised controlled trials that have compared any new-generation antidepressant with placebo for the acute treatment of major depressive disorder in children and adolescents, in the following databases.
Antidepressants for depressive disorder in children and adolescents: a database of randomised controlled trials
TLDR
This database provides information on nearly all randomised controlled trials of antidepressants in children and adolescents and could help to promote research on evidence-based practice in the treatment of depressive disorder inChildren and adolescents.
Fluoxetine in the Management of Major Depressive Disorder in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials
TLDR
Fluxetine demonstrates significant improvements in symptom intensity control in young patients suffering from MDD and is considered well tolerated with similar rates of trials discontinuation; however, fluoxetine was associated with a higher risk of headache and rash side effects.
Comparing the effectiveness, safety and tolerability of interventions for depressive symptoms in people with multiple sclerosis: a systematic review and network meta-analysis protocol
TLDR
A systematic review and network meta-analysis is conducted to compare efficacy and safety of psychological, pharmaceutical, physical and magnetic stimulation interventions for depression in people with multiple sclerosis.
Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis
TLDR
Compared with placebo, SSRIs and SNRIs are more beneficial than placebo in children and adolescents; however, the benefit is small and disorder specific, yielding a larger drug-placebo difference for AD than for other conditions.
...
...

References

SHOWING 1-10 OF 64 REFERENCES
Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: study protocol for a systematic review and network meta-analysis
TLDR
This work integrates the direct and indirect evidence using network meta-analysis to create hierarchies of antidepressant medications in the treatment of depression in children and adolescents, and aims to provide useful information on antidepressant treatment for child and adolescent depression.
Newer generation antidepressants for depressive disorders in children and adolescents.
TLDR
There was evidence that those treated with an antidepressant had lower depression severity scores and higher rates of response/remission than those on placebo, and fluoxetine might be the medication of first choice given guideline recommendations.
Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.
TLDR
The results of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term treatment for children and adolescents with MDD.
Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial.
TLDR
Paroxetine and clomipramine exhibit similar efficacy in adolescent depression, and these data support the serotonin hypothesis but do not confirm it in the absence of a placebo arm.
Efficacy of antidepressants in juvenile depression: meta-analysis
TLDR
Antidepressants of all types showed limited efficacy in juvenile depression, but fluoxetine might be more effective, especially in adolescents.
COMPARISON OF EFFICACY OF FLUOXETINE WITH NORTRIPTYLINE IN TREATMENT OF MAJOR DEPRESSION IN CHILDREN AND ADOLESCENTS: A DOUBLE-BLIND STUDY
TLDR
Evidence is provided in favor of an efficacy advantage of fluoxetine over nortriptyline in the treatment of depression in children and adolescents.
The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial
TLDR
Fluoxetine was not superior to placebo in alleviating depressive symptoms or in decreasing rates of positive drug screens in the acute treatment of adolescents with depression and a concomitant substance use disorder.
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
TLDR
The combination of fluoxetine with CBT offered the most favorable tradeoff between benefit and risk for adolescents with major depressive disorder.
Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial.
TLDR
Fluoxetine 20 mg daily appears to be well tolerated and effective for acute treatment of MDD in child and adolescent outpatients.
...
...